Conflict of interest

Y.S. reports research fundings from Chugai Pharmaceutical Co., Ltd. M.I. reports consulting fees from AstraZeneca K.K. and MSD K.K., honoraria from AstraZeneca K.K., Guardant Health Japan Corp., Incyte Biosciences Japan G.K., MSD K.K. and Taiho Pharmaceutical Co., Ltd., and research fundings from AstraZeneca K.K., Boehringer Ingelheim Co., Ltd., Eisai Co., Ltd., Eli Lilly and Company, J-Pharma Co., Ltd., Merck Biopharma Co., Ltd. and Ono Pharmaceutical Co., Ltd. J.M. reports honoraria from Chugai Pharmaceutical Co., Ltd. and Taiho Pharmaceutical Co., Ltd., and his spouse is an employee of Pfizer Japan Inc. C.M. reports honoraria from AstraZeneca K.K., Eisai Co., Ltd., Guardant Health Japan Corp., MSD K.K., Myriad Genetic G.K., Novartis Pharma K.K., Nihon Servier Co., Ltd., Taiho Pharmaceutical Co., Ltd., Toray Industries, Inc., and Yakult Honsha Co., Ltd., and research fundings from AstraZeneca K.K., Boehringer Ingelheim Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., J-Pharma Co., Ltd., Merck Biopharma Co., Ltd., Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., and Yakult Honsha Co., Ltd. T.O. reports grants from AstraZeneca K.K., Bristol Myers Squibb K.K., Chiome Bioscience Inc., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Incyte Biosciences Japan G.K., MSD K.K., Novartis Pharma K.K., Syneos Health Clinical K.K. and Sysmex Corp., consulting fees from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Eisai Co., Ltd., FUJIFILM Toyama Chemical Co., Ltd., Nihon Servier Co., Ltd., Novartis Pharma K.K. and Ono Pharmaceutical Co., Ltd., honoraria from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Johnson & Johnson, Myriad Genetic G.K., Nihon Servier Co., Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Syneos Health Clinical K.K., Taiho Pharmaceutical Co., Ltd. and Yakult Honsha Co., Ltd. S.K. reports honoraria from AstraZeneca K.K. and MSD K.K. H.I. reports honoraria from AstraZeneca K.K., Boston Scientific Corp., Kaneka Medix Corp., Nihon Servier Co., Ltd., Novartis Pharma K.K., SB-KAWASUMI LABORATORIES, INC. and Yakult Honsha Co., Ltd., fees for promotional materials from Medico’s Hirata Inc., research fundings from Boehringer Ingelheim Co., Ltd., Nihon Servier Co., Ltd., Novartis Pharma K.K. and Ono Pharmaceutical Co., Ltd., and he is a participant on an advisory board of Nihon Servier Co., Ltd. T.T. reports honoraria from AstraZeneca K.K. and Chugai Pharmaceutical Co., Ltd. N.O. reports honoraria from AstraZeneca K.K. A.T. reports honoraria from AstraZeneca K.K., Nihon Servier Co., Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Teijin Pharma, Ltd. and Yakult Honsha Co., Ltd. S.S. reports research fundings from AstraZeneca K.K., Delta-Fly Pharma, Inc., Incyte Biosciences Japan G.K. and Nihon Servier Co., Ltd. N.M. reports research fundings from AstraZeneca K.K., Boehringer Ingelheim Co., Ltd., Incyte Biosciences Japan G.K., MSD K.K., Nihon Servier Co., Ltd., Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc. and Seagen Inc. S.S. reports research fundings from Amino Up Co., Ltd., Boston Scientific Corp. and Nihon Servier Co., Ltd. M.O. reports honoraria from MSD K.K., Nihon Servier Co., Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd. and Yakult Honsha Co., Ltd. M.U. reports honoraria from Taiho Pharmaceutical Co., Ltd. and Yakult Honsha Co., Ltd., and fundings from Taiho Pharmaceutical Co., Ltd. The other authors have nothing to declare for this study.

Ethical approval statement, patient consent statement, and permission to reproduce material from other sources

JCOG1113 was conducted in accordance with the 1964 Declaration of Helsinki, its later amendments and Japanese Ethical Guidelines for Clinical Research, and the study protocol was approved by the institutional review board of each participating institution. The written informed consent was obtained from all participants of JCOG1113.